Author: Tom Wilemon
Precision radiation aids patient’s cancer battle
Dec. 6, 2018—After undergoing precision radiation therapy at Vanderbilt-Ingram Cancer Center, 90-year-old Imogene Stranch quickly returned to her workout routine at the Bellevue Family YMCA.
Neuromodulation Society honors Hacker’s Parkinson’s research
Dec. 6, 2018—Mallory Hacker, PhD, research assistant professor of Neurology, is the 2019 recipient of the Kumar New Investigator Award from the North American Neuromodulation Society.
New epilepsy monitoring systems collect better data
Nov. 15, 2018—New epilepsy monitoring systems at Vanderbilt University Medical Center are providing neurologists better data for assessing adult and pediatric patients.
Immunotherapies linked to specific heart complications
Nov. 15, 2018—In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.
Clinical fellows program bolstered by new NCI grant
Nov. 8, 2018—A new grant from the National Cancer Institute (NCI) will fund an intensively mentored training experience for clinical fellows at Vanderbilt University Medical Center for the next five years.
Multi-factor authentication coming for C2HR users
Nov. 8, 2018—Like employees the world over, Vanderbilt University Medical Center email system users are prey to frequent email spoofs, by which would-be identity thieves attempt to steal employee login credentials.
Cancer Center among best in nation for stem cell transplant survival
Nov. 2, 2018—Vanderbilt-Ingram Cancer Stem Cell Transplant ranks among the best in the nation for donor stem cell transplant survival rates among large centers, according to an annual report.
Warner’s medical informatics research recognized
Nov. 1, 2018—Jeremy Warner, MD, is the 2018 recipient of the New Investigator Award from the American Medical Informatics Association (AMIA).
Mary Kay Foundation grant to bolster immunotherapy research
Oct. 25, 2018—An immunotherapy research initiative at Vanderbilt University Medical Center is among those being supported by the Mary Kay Foundation, which has announced $1.2 million in funding that will be equally shared among 12 cancer research institutions.
Combination therapy improves small-cell lung cancer survival
Oct. 25, 2018—Patients with stage IV small-cell lung cancer lived longer when given the immunotherapy atezolizumab with chemotherapy, setting the stage for what could become the first new treatment approved in decades for this particularly aggressive form of lung cancer.
Grant enhances study of new chemotherapy targets
Oct. 18, 2018—Vanderbilt chemists have been awarded $7.2 million over the next five years from the National Cancer Institute to lead an initiative to better understand how a combination chemotherapy for breast cancer targets DNA.
Cancer Center investigators awarded Komen grants
Oct. 11, 2018—Four Vanderbilt-Ingram Cancer Center (VICC) investigators have received financial support from Susan G. Komen for breast cancer research.
